Company news

Jiangsu Hengrui Pharmaceuticals Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

November 6, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on FDA Acceptance of the Resubmitted Biologics License Application for Camrelizumab for Injection

November 4, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice

November 4, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 6th Meeting of the 10th Board of Directors

November 3, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares

November 2, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion in the Priority Review Program

October 29, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice

October 28, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice

October 28, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Report for Q3 2026

October 27, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 5th Meeting of the 10th Board of Directors

October 27, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Drug Registration Approval

October 27, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice

October 26, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice

October 22, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares

October 22, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice

October 13, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance by the EMA of the Application for Drug Marketing Authorization

October 8, 2026

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares

October 8, 2026

Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer

October 8, 2026

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

September 29, 2026

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

September 24, 2026

Announcement on Initial Repurchase of the Company's A-Shares

September 17, 2026

Notice on Convening the 1st Extraordinary General Meeting in 2026

September 8, 2026

Announcement on Progress in Repurchasing A-Shares

September 2, 2026

Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning A-Share Repurchase

August 26, 2026

Announcement on Implementation Result of Shares Repurchase and Share Changes

August 19, 2026

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization

July 29, 2026

Announcement on Obtaining Orphan Drug Designation from the US FDA

July 27, 2026

Announcement on Obtaining Drug Registration Approval

July 23, 2026

Announcement on Progress in A-share Repurchase

July 19, 2026

Announcement on Obtaining Notice of Approval for Drug Clinical Trial

July 16, 2026

Announcement on Inclusion of Drug in Breakthrough Therapy Designation List

July 13, 2026

Announcement on Inclusion of Key Pharmaceutical Products of the Company in the National Essential Medicines List

July 10, 2026

Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces Positive Topline Data from Two Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535

July 7, 2026

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program

July 2, 2026

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

June 30, 2026

Announcement on Obtaining Drug Registration Approval

June 25, 2026

Announcement on Withdrawal of Drug Registration Application

June 23, 2026

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA

June 22, 2026

Announcement on Obtaining Notice of Approval for Drug Clinical Trial

June 16, 2026

Announcement on Progress in A-share Repurchase

June 2, 2026

Announcement on Convening the Q1 2026 Performance Briefing

May 27, 2026

Announcement on Implementation of Dividend Distribution for 2025

May 20, 2026

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

May 12, 2026

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

May 11, 2026

Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors

April 29, 2026

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

April 22, 2026

Announcement on Inclusion of Drug in Breakthrough Therapy Designation List

April 20, 2026

Announcement on Resolutions of the 1st Meeting of the 10th Board of Directors

April 16, 2026

Announcement on Completion of Unlocking the Lockup Period of Employee Stock Ownership Plan

April 3, 2026

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

March 30, 2026

Older news releases →

Decks

The 5 newest of 9 decks. Every deck is listed under its year.